Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Status:
Recruiting
Trial end date:
2022-06-15
Target enrollment:
Participant gender:
Summary
Open-label, phase II, basket trial. This trial is a screening program for abemaciclib
efficacy in multiple platinum-resistant tumour types by using metabolic imaging (PERCIST) and
RECIST v1.1 criteria.
Based on the rate of FDG-avidity and the absence of deactivation of the Rb gene function in
more than 95% of cases, we propose to define 5 tumour types of interest in a preliminary
stage:
1. Platinum-refractory esophageal adenocarcinoma (ADC)
2. Platinum-refractory esophageal squamous cell carcinoma (SCC)
3. Platinum-refractory cholangiocarcinoma
4. Platinum-refractory and progressive after immunotherapy urothelial cancer
5. Platinum-refractory endometrial cancer